Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $12.77 and traded as low as $12.45. Astria Therapeutics shares last traded at $12.81, with a volume of 1,076,980 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ATXS shares. HC Wainwright lowered Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Jefferies Financial Group downgraded shares of Astria Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $30.00 to $13.00 in a report on Tuesday, October 14th. Cantor Fitzgerald cut shares of Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Wednesday, November 12th. Citizens Jmp downgraded shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 15th. Finally, Oppenheimer downgraded Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Astria Therapeutics currently has an average rating of “Hold” and a consensus price target of $24.50.

Astria Therapeutics Price Performance

The stock’s 50-day moving average price is $12.77 and its 200-day moving average price is $9.60. The company has a market cap of $731.19 million, a P/E ratio of -5.99 and a beta of 0.01.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The company had revenue of $0.71 million for the quarter, compared to analyst estimates of $10.67 million. As a group, analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. Russell Investments Group Ltd. raised its position in shares of Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 3,506 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,557 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Astria Therapeutics in the 3rd quarter valued at $98,000. AXQ Capital LP bought a new position in shares of Astria Therapeutics in the 3rd quarter valued at $115,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth $145,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.